2236. Zidebactam Phase 1 Single Ascending Dose and Crossover Study in Healthy Subjects
Session: Poster Abstract Session: New Antibiotics in Development
Saturday, October 29, 2016
Room: Poster Hall
  • 2236 Poster ID week.pdf (197.6 kB)
  • Background: Zidebactam (WCK 5107) is a new chemical entity (NCE) exhibiting a novel mode of action. WCK 5222, a combination of cefepime and β-lactam enhancer zidebactam, is being developed to provide a therapeutic option for the treatment of infections caused by MDR Gram-negative pathogens harbouring metallo-β-lactamases (MBL) associated with enterics and Pseudomonas as well as carbapenem-hydrolysing (CHDL) Class D β-lactamases in Acinetobacter spp and Klebsiella. WCK 5222 is based on a novel ‘enhancer’ mechanism that involves complementary binding to essential PBPs by its constituents, cefepime and zidebactam.

    Methods: 70 healthy volunteers were enrolled in 7 single ascending dose (SAD) cohorts (8 subjects on zidebactam and 2 on placebo in each cohort) to receive intravenous (IV) zidebactam ranging from 250 mg to 3000 mg in a double-blind manner. 9 subjects each in 2 crossover cohorts received 3 IV treatments in a randomized treatment order: zidebactam alone, cefepime alone, and combination of cefepime and zidebactam at 2 dose levels of zidebactam (1000 mg and 2000 mg), each followed by a 3 day washout period.

    Results: In the SAD cohorts, the exposure of zidebactam (AUC0-Inf) increased in a dose-proportional manner from 44.3 to 458 µg*h/mL and Cmax from 16.5 to 174 µg/mL over the 250 mg – 3000 mg dose range. The elimination half-life ranged from 1.84 to 2.39 h. For the cross-over cohorts, AUC0-Inf, Cmax, t1/2, and related PK parameters were consistent between 2 treatments (drugs administered alone versus in combination), and for both zidebactam and cefepime. More than 80% of the administered dose of zidebactam and cefepime was excreted as unchanged drug within 0 to 6 h postdose.

    All treatment-emergent adverse events (TEAEs) were mild (except for 2 events of headache, which were moderate in severity). No deaths, SAEs or discontinuations due to AEs were reported during the study.


    • Zidebactam increases in PK parameters were dose proportional within the 250 mg to 3000 mg dose range.
    • No significant PK interaction was observed when zidebactam and cefepime were co‑administered at two different zidebactam dose levels.
    • Zidebactam was safe and well tolerated up to 3000 mg alone, or in combination with cefepime at the 2 dose levels tested for zidebactam.
    Ashima Bhatia, MD, Mugdha Gupta, MBA and Rakesh Chugh, MD, Clinical Development, WOCKHARDT, MUMBAI, India


    A. Bhatia, None

    M. Gupta, None

    R. Chugh, None

    Previous Abstract | Next Abstract >>

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.